Tau expression levels from various adeno‐associated virus vector serotypes produce graded neurodegenerative disease states
- 31 March 2008
- journal article
- research article
- Published by Wiley in European Journal of Neuroscience
- Vol. 27 (7) , 1615-1625
- https://doi.org/10.1111/j.1460-9568.2008.06161.x
Abstract
Neurodegenerative diseases involving neurofibrillary tangle pathology are pernicious. By expressing the microtubule‐associated protein tau, a major component of tangles, with a viral vector, we induce neuropathological sequelae in rats that are similar to those seen in human tauopathies. We tested several variants of the adeno‐associated virus (AAV) vector for tau expression in the nigrostriatal system in order to develop models with graded onset and completeness. Whereas previous studies with AAV2 tau vectors produced partial lesions of the nigrostriatal system, AAV9 or AAV10 tau vectors were more robust. These vectors had formidable efficacy relative to 6‐hydroxydopamine for dopamine loss in the striatum. Time‐courses for tau transgene expression, dopamine loss and rotational behavior tracked the disease progression with the AAV9 tau vector. There was a nearly complete lesion over a delayed time‐course relative to 6‐hydroxydopamine, with a sequence of tau expression by 1 week, dopamine loss by 2 weeks and then behavior effect by 3–4 weeks. Relative to AAV2 or AAV8, tau expression from AAV9 or AAV10 peaked earlier and caused more dopamine loss. Varying vector efficiencies produced graded states of disease up to nearly complete. The disease models stemming from the AAV variants AAV9 or AAV10 may be useful for rapid drug screening, particularly for tau diseases that affect the nigrostriatal system, such as progressive supranuclear palsy.Keywords
This publication has 45 references indexed in Scilit:
- The phosphorylation state of Ser-129 in human α-synuclein determines neurodegeneration in a rat model of Parkinson diseaseProceedings of the National Academy of Sciences, 2008
- AAV8, 9, Rh10, Rh43 Vector Gene Transfer in the Rat Brain: Effects of Serotype, Promoter and Purification MethodMolecular Therapy, 2008
- Neuropathologic diagnostic and nosologic criteria for frontotemporal lobar degeneration: consensus of the Consortium for Frontotemporal Lobar DegenerationActa Neuropathologica, 2007
- Enhanced Survival of the LINCL Mouse Following CLN2 Gene Transfer Using the rh.10 Rhesus Macaque-derived Adeno-associated Virus VectorMolecular Therapy, 2007
- Dopaminergic neuron loss and up‐regulation of chaperone protein mRNA induced by targeted over‐expression of alpha‐synuclein in mouse substantia nigraJournal of Neurochemistry, 2006
- Anti-Aβ single-chain antibody delivery via adeno-associated virus for treatment of Alzheimer's diseaseNeurobiology of Disease, 2006
- Efficient Neuronal Gene Transfer with AAV8 Leads to Neurotoxic Levels of Tau or Green Fluorescent ProteinsMolecular Therapy, 2006
- Rapid Neurofibrillary Tangle Formation after Localized Gene Transfer of Mutated TauThe American Journal of Pathology, 2004
- An R5L τ mutation in a subject with a progressive supranuclear palsy phenotypeAnnals of Neurology, 2002
- Recombinant AAV vectors containing the foot and mouth disease virus 2A sequence confer efficient bicistronic gene expression in cultured cells and rat substantia nigra neuronsGene Therapy, 2001